Home - Products - Others - Other Targets - Crizanlizumab

Crizanlizumab

CAS No. 1690318-25-2

Crizanlizumab( —— )

Catalog No. M36878 CAS No. 1690318-25-2

Crizanlizumab (Adakveo) is a humanized monoclonal antibody against P-selectin for the prevention of pain crises in sickle cell disease.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
5MG	748	In Stock
10MG	1254	In Stock
25MG	1862	In Stock
50MG	2465	In Stock
100MG	Get Quote	In Stock
200MG	Get Quote	In Stock
500MG	Get Quote	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Crizanlizumab
Note

Research use only, not for human use.
Brief Description

Crizanlizumab (Adakveo) is a humanized monoclonal antibody against P-selectin for the prevention of pain crises in sickle cell disease.
Description

Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Others
Target

Other Targets
Recptor

Others
Research Area

——
Indication

——

Chemical Information

CAS Number

1690318-25-2
Formula Weight
Molecular Formula

——
Purity

>98% (HPLC)
Solubility

——
SMILES

——
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. Hannah A. Blair, et al. Crizanlizumab: First Approval. Drugs. 80, 79-84 (2020).

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

BPDBA

BPDBA is an effective, selective, and non-competitive inhibitor of the betaine/GABA transporter (BGT-1), displaying inhibitory activity against human BGT-1 and mouse GAT2, with IC50 values of 20 μM and 35 μM, respectively.
Brandioside

Brandioside shows strong antioxidant, and neuroprotective effects, it significantly attenuates glutamate-induced neurotoxicity at concentrations ranging from 0.1 to 10 microM; it exhibits significant inhibition of advanced glycation end product formation with the IC50 value of 4.6-25.7 μM.
(R,S)-Equol

S-equol and R/S-equol estrogen receptor α2-selective phytoSERM treatments have potentiation of brain mitochondrial function.

Sign In Join Free